Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
An TaFelicitas KühneMaren LaurenzChristof von EiffSophie WarrenJohnna E PerdrizetPublished in: Infectious diseases and therapy (2024)
PCV20 3+1 dominated both PCV13 2+1 and PCV15 2+1 over 10 years. Replacing lower-valent PCVs with PCV20 would result in greater clinical and economic benefits, given PCV20's broader serotype coverage.
Keyphrases